Recruiting studies: Nonsmall Cell Lung Cancer Stage Iii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086 The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
NA · 4 location(s) · Thomas Jefferson University · NCT05502523 Tumor Treating Fields for Locally Advanced NSCLC
Phase 1 · 1 location(s) · University of Utah · NCT06124118 Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Phase N/A · 1 location(s) · AIO-Studien-gGmbH · NCT02622581 Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03872661 BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
Phase 2 · 1 location(s) · Brown University · NCT04933903 Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07609121 Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stag
Phase 2 · 25 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06656598 A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
NA · 1 location(s) · All India Institute of Medical Sciences · NCT07565987 Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT06634056 Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell
Phase 1/Phase 2 · 9 location(s) · National Cancer Institute (NCI) · NCT07012031 Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mut
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT04853342 Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to
Phase 3 · 270 location(s) · NRG Oncology · NCT06500455 Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Phase 3 · 3 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT06041776 Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
Phase N/A · 10 location(s) · Shanghai Chest Hospital · NCT07528066 Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Vestre Viken Hospital Trust · NCT05344209 A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT05940532 Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Phase 2 · 1 location(s) · Wake Forest University Health Sciences · NCT05692635 A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small C
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07082179 Exploratory Biomarker Analysis of Neoadjuvant Chemoimmunotherapy Followed by Pulmonary Resection in Stage II-III Non-Sma
Phase N/A · 1 location(s) · Yonsei University · NCT06907160 Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127 A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell L
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT05487391 The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment
Phase 2 · 1 location(s) · The Third Xiangya Hospital of Central South University · NCT07138755 The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
NA · 27 location(s) · Radboud University Medical Center · NCT06082492 A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
NA · 1 location(s) · Mayo Clinic · NCT06122064 A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Phase 3 · 7 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT04316364 Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage I
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07410975 Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04892953 Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
Phase 3 · 2 location(s) · Hunan Province Tumor Hospital · NCT07251582

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.